An avian cell line designed for production of highly attenuated viruses.
about
Matrix and backstage: cellular substrates for viral vaccinesVaccines: the Fourth CenturyCell culture-based influenza vaccines: A necessary and indispensable investment for the futureContinuous cell lines as a production system for influenza vaccines.Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses.Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.Continuous influenza virus production in cell culture shows a periodic accumulation of defective interfering particles.The avian cell line AGE1.CR.pIX characterized by metabolic flux analysisAuthentication of the R06E fruit bat cell line.Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.The strategic use of novel smallpox vaccines in the post-eradication world.Clinical applications of attenuated MVA poxvirus strain.Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains.Designing cell lines for viral vaccine production: Where do we stand?Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Recombinant modified vaccinia virus Ankara-based malaria vaccines.Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines.Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.Propagation of viruses infecting waterfowl on continuous cell lines of Muscovy duck (Cairina moschata) origin.Evaluating differences of metabolic performances: statistical methods and their application to animal cell cultivations.A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium.CAP, a new human suspension cell line for influenza virus production.Quantitative characterization of metabolism and metabolic shifts during growth of the new human cell line AGE1.HN using time resolved metabolic flux analysis.Purification of modified vaccinia virus Ankara from suspension cell culture.A novel genotype of MVA that efficiently replicates in single cell suspensions.Constitutively elevated levels of SOCS1 suppress innate responses in DF-1 immortalised chicken fibroblast cells.Cell culture-based production of defective interfering particles for influenza antiviral therapy.Animal Cell Expression Systems.Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production
P2860
Q27025941-A49C208B-F2C9-4AE9-8776-E8B9132FCA1EQ27490454-D187D727-EA15-4BF4-A1D5-9006676C9003Q28084739-5E831831-9A48-4BA2-AF68-2502E1B19CF2Q30382947-0C8B4289-C32E-4608-A24A-BD12D5A36A27Q34175601-F514CBD8-F720-4C5C-AE32-C9AFC87D098AQ34461309-7A8FA9BB-7339-426A-A155-D8684FB740F7Q34988338-0F44DE49-EB44-46D4-80EB-358D201B2637Q35215836-D02789A3-DB68-43A1-8DB4-D4BC8F5EE1C2Q36067726-CC4E62D3-30E2-4AF3-A5E8-AFB758B65E37Q37209483-E265AA52-6CCF-45CB-A80C-BC71487EF714Q37909421-CE9CD064-90A1-4075-B6ED-4123B2F4EDBBQ38156198-DD9E0F58-5FDF-4FCB-B5DD-486811DB8538Q38162948-25B0B66E-C430-4B1F-9B13-917E9A126EC5Q38436738-68D78105-DA04-4DD5-89FF-4B36AF9BEBF2Q38443390-1E6D9AE0-E942-40FE-A0A4-B494EB55D9C8Q38554795-8A73CC2E-1832-4E2F-AA63-C417AC7EC86CQ38618898-2FB38AA0-1909-479C-A3E7-8833F7BE2C65Q38694270-8AF7E463-5247-45C7-9A55-7E3A4480E53CQ38799241-E8051BE8-9F4B-4523-B3BD-71F133554A02Q38970262-12ED5755-7B81-4C3D-9D89-34594442BEFBQ38978381-28536006-67A8-473F-A09C-6AC5494786F4Q39169143-2121AD11-751F-41D4-BB69-99F96BCE5D0CQ39207337-80E761D2-8360-4700-9DD9-BBD0E8ECEA4AQ39310257-18D21B64-6112-4581-A314-5887087CF249Q39615011-85774320-3D42-4BE7-AF8B-C29E928491F0Q46251065-752086BA-72D4-49FE-BB05-AD2F4CF36AFBQ46429365-3CFC53D9-1BE1-412C-A7DC-82B92EF574F6Q47094073-BF53D814-8C04-4AFA-BA71-A3B65F4F9013Q47284499-53346473-EF16-4DB4-84D0-EF4D059C3D61Q47406183-12F87C46-0873-4A02-B49E-D59478031FBDQ56341510-793F2ED3-88B2-4BA9-B94E-F979C9254A5E
P2860
An avian cell line designed for production of highly attenuated viruses.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
An avian cell line designed for production of highly attenuated viruses.
@en
An avian cell line designed for production of highly attenuated viruses.
@nl
type
label
An avian cell line designed for production of highly attenuated viruses.
@en
An avian cell line designed for production of highly attenuated viruses.
@nl
prefLabel
An avian cell line designed for production of highly attenuated viruses.
@en
An avian cell line designed for production of highly attenuated viruses.
@nl
P2093
P4510
P1433
P1476
An avian cell line designed for production of highly attenuated viruses.
@en
P2093
Andreas Neubert
Sabine Breul
Stefanie Beilfuss
Volker Sandig
P304
P356
10.1016/J.VACCINE.2008.11.066
P407
P50
P577
2008-12-09T00:00:00Z